The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine

S. I. Al-Azzam, A. M. Alkhateeb, O. Al-Azzeh, K. H. Alzoubi, O. F. Khabour

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Study Objective: Several factors can affect achieving the goals with levothyroxine (L-T4) therapy. This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene. Design and setting: This is a cross-sectional correlation study. The setting was the diabetes and endocrinology clinics at 2 Jordanian Hospitals. Methodology: Patients with primary hypothyroidism who are controlled on stable L-T4 replacement therapy were recruited and thyroid function test was performed. Genetic analysis to detect 4 single nucleotide polymorphisms (SNPs) rs225011, rs7140952, rs225012 and rs2839858 in DIO2 gene was carried out using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP). Results: There was no correlation between the 4 SNPs in DIO2 gene and replacement doses of L-T4, whereas a statistical significance was found between rs7140952 and central obesity (P<0.05), and systolic and diastolic blood pressure (P<0.05). The dose of L-T4 was associated with lower levels of TSH, fT4, central obesity, body mass index and waist circumference. Conclusion: While L-T4 dose is associated with several positive effects on hypothyroid patients, none of the examined SNPs in DIO2 is correlated with replacement doses of the drug. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.

Original languageEnglish
Pages (from-to)300-305
Number of pages6
JournalExperimental and Clinical Endocrinology and Diabetes
Volume121
Issue number5
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Iodide Peroxidase
Abdominal Obesity
Thyroxine
Single Nucleotide Polymorphism
Blood Pressure
Genes
Thyroid Function Tests
Endocrinology
Waist Circumference
Hypothyroidism
Restriction Fragment Length Polymorphisms
Body Mass Index
Therapeutics
Cross-Sectional Studies
Polymerase Chain Reaction
Pharmaceutical Preparations

Keywords

  • deiodinase type||
  • hypothyroid
  • Jordan
  • levothyroxine
  • polymorphism

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine. / Al-Azzam, S. I.; Alkhateeb, A. M.; Al-Azzeh, O.; Alzoubi, K. H.; Khabour, O. F.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 121, No. 5, 2013, p. 300-305.

Research output: Contribution to journalArticle

Al-Azzam, S. I. ; Alkhateeb, A. M. ; Al-Azzeh, O. ; Alzoubi, K. H. ; Khabour, O. F. / The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine. In: Experimental and Clinical Endocrinology and Diabetes. 2013 ; Vol. 121, No. 5. pp. 300-305.
@article{d2cbd6f4b78748d2806e61b55baa54ff,
title = "The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine",
abstract = "Study Objective: Several factors can affect achieving the goals with levothyroxine (L-T4) therapy. This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene. Design and setting: This is a cross-sectional correlation study. The setting was the diabetes and endocrinology clinics at 2 Jordanian Hospitals. Methodology: Patients with primary hypothyroidism who are controlled on stable L-T4 replacement therapy were recruited and thyroid function test was performed. Genetic analysis to detect 4 single nucleotide polymorphisms (SNPs) rs225011, rs7140952, rs225012 and rs2839858 in DIO2 gene was carried out using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP). Results: There was no correlation between the 4 SNPs in DIO2 gene and replacement doses of L-T4, whereas a statistical significance was found between rs7140952 and central obesity (P<0.05), and systolic and diastolic blood pressure (P<0.05). The dose of L-T4 was associated with lower levels of TSH, fT4, central obesity, body mass index and waist circumference. Conclusion: While L-T4 dose is associated with several positive effects on hypothyroid patients, none of the examined SNPs in DIO2 is correlated with replacement doses of the drug. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.",
keywords = "deiodinase type||, hypothyroid, Jordan, levothyroxine, polymorphism",
author = "Al-Azzam, {S. I.} and Alkhateeb, {A. M.} and O. Al-Azzeh and Alzoubi, {K. H.} and Khabour, {O. F.}",
year = "2013",
doi = "10.1055/s-0032-1331695",
language = "English",
volume = "121",
pages = "300--305",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "5",

}

TY - JOUR

T1 - The role of type II deiodinase polymorphisms in clinical management of hypothyroid patients treated with levothyroxine

AU - Al-Azzam, S. I.

AU - Alkhateeb, A. M.

AU - Al-Azzeh, O.

AU - Alzoubi, K. H.

AU - Khabour, O. F.

PY - 2013

Y1 - 2013

N2 - Study Objective: Several factors can affect achieving the goals with levothyroxine (L-T4) therapy. This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene. Design and setting: This is a cross-sectional correlation study. The setting was the diabetes and endocrinology clinics at 2 Jordanian Hospitals. Methodology: Patients with primary hypothyroidism who are controlled on stable L-T4 replacement therapy were recruited and thyroid function test was performed. Genetic analysis to detect 4 single nucleotide polymorphisms (SNPs) rs225011, rs7140952, rs225012 and rs2839858 in DIO2 gene was carried out using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP). Results: There was no correlation between the 4 SNPs in DIO2 gene and replacement doses of L-T4, whereas a statistical significance was found between rs7140952 and central obesity (P<0.05), and systolic and diastolic blood pressure (P<0.05). The dose of L-T4 was associated with lower levels of TSH, fT4, central obesity, body mass index and waist circumference. Conclusion: While L-T4 dose is associated with several positive effects on hypothyroid patients, none of the examined SNPs in DIO2 is correlated with replacement doses of the drug. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.

AB - Study Objective: Several factors can affect achieving the goals with levothyroxine (L-T4) therapy. This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene. Design and setting: This is a cross-sectional correlation study. The setting was the diabetes and endocrinology clinics at 2 Jordanian Hospitals. Methodology: Patients with primary hypothyroidism who are controlled on stable L-T4 replacement therapy were recruited and thyroid function test was performed. Genetic analysis to detect 4 single nucleotide polymorphisms (SNPs) rs225011, rs7140952, rs225012 and rs2839858 in DIO2 gene was carried out using the polymerase chain reaction-based restriction fragment length polymorphism assay (PCR-RFLP). Results: There was no correlation between the 4 SNPs in DIO2 gene and replacement doses of L-T4, whereas a statistical significance was found between rs7140952 and central obesity (P<0.05), and systolic and diastolic blood pressure (P<0.05). The dose of L-T4 was associated with lower levels of TSH, fT4, central obesity, body mass index and waist circumference. Conclusion: While L-T4 dose is associated with several positive effects on hypothyroid patients, none of the examined SNPs in DIO2 is correlated with replacement doses of the drug. However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.

KW - deiodinase type||

KW - hypothyroid

KW - Jordan

KW - levothyroxine

KW - polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84877832820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877832820&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1331695

DO - 10.1055/s-0032-1331695

M3 - Article

C2 - 23329579

AN - SCOPUS:84877832820

VL - 121

SP - 300

EP - 305

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 5

ER -